SOSV, the venture capital firm behind HAX in Newark, recently announced that its new HAX Plasma Forge will establish its permanent headquarters at SRI’s historic WesT Windsor campus, where...
California-based pharma developer Gilead Sciences announced on November 21 that it would step heartily into the hepatitis market with the $11 billion all-cash acquisition...